News | Hypertension | September 25, 2015

Study Reveals Medisafe Medication Management Platform Significantly Lowers Blood Pressure

Mobile application promotes better adherence to blood pressure medication, resulting in lowered risk profiles for stroke and other cardiovascular disease

Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence

September 25, 2015 — Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which showed app users with stage 1 or stage 2 hypertension decreased their systolic blood pressure by 17.7 and 25.3 mmHg, respectively, within 30 days. As the sole biomarker to measure hypertension and with a direct connection to clinical outcomes, blood pressure served as a surrogate for measuring medication adherence in this study.

An estimated 78 million adults in the United States have hypertension – defined by systolic levels above 140 mmHg and diastolic levels above 90 mmHg. This figure is projected to rise to 111 million in 2030, due in part to low rates of medication adherence, as only 51 percent of Americans treated for hypertension are adherent to the long-term therapy prescribed by their doctors.

Medisafe's study examined three risk profiles:

  • Prehypertension (BP 120 to 139 mmHg systolic);
  • Hypertension stage 1 (BP 140 to 160 mmHg systolic); and
  • Hypertension stage 2 (BP above 160 mmHg systolic).

To be included in the study and assigned to a risk profile, users needed at least two readings within a risk profile. These readings were then averaged to provide a baseline. The same logic and calculation was applied for the final week of readings. Medisafe limited the analysis to users reporting readings via their "connected devices" – WiFi- or Bluetooth-enabled blood pressure cuffs automatically transmitting levels to Medisafe – to eliminate the potential for self-reporting bias.

Medisafe framed its research around three leading clinical reference points:

  • According to the American Heart Association, reducing average population systolic blood pressure by 12 to 13 mmHg could reduce incidence of stroke by 37 percent, coronary heart disease by 21 percent and cardiovascular disease mortality by 25 percent;
  • An annual National Institutes of Health (NIH) Report suggests that decreases in systolic blood pressure of 5 mmHg would result in an estimated 14 percent overall reduction in mortality due to stroke, a 9 percent reduction in mortality due to CHD and a 7 percent decrease in all-cause mortality; and
  • The just-published, NIH-funded SPRINT study revealed that even more aggressive treatment targeting 120 mmHg systolic – as opposed to 140 mmHg – led to a 30 percent lower risk of adverse cardiovascular events and 25 percent lower risk of death.

The Medisafe study results found:  

  • 100 percent of stage 2 users reduced their systolic blood pressure. The mean result was a 25.3 mmHg improvement in 30 days;
  • 86 percent of stage 2 users reduced their risk category (i.e., moved to hypertension stage 1 of 140 to 160, or below);
  • 66 percent of stage 1 users reduced their systolic blood pressure. The mean result was a 17.7 mmHg improvement in 30 days;
  • 56 percent of stage 1 users reduced their risk category (i.e., moved to prehypertension systolic of 120 to 139, or below);
  • Against a hypothesis of greater than 5 mmHg decrease in systolic, users in both stages showed high statistical significance with p-values below .001;
  • Users in both stages sustained lower levels, suggesting persisted adherence, for at least an additional 40 days, after which time insufficient data were available; and
  • 23 percent of prehypertension and 9 percent of stage 1 users reduced their systolic blood pressure into the normal range below 120 mmHg.

Study results are consistent with Medisafe's previously announced findings that its users are 86 percent adherent versus the World Health Organization’s (WHO) estimate of 50 percent for the nation as a whole.

For more information: www.medisafe.com

Related Content

SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension| August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension| March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Overlay Init